Perkin Elmer has announced its acquisition of Shanghai-based Sym-Bio Lifescience, a provider of diagnostics instruments and related reagents.
The acquisition is expected to have no material impact on Perkin Elmer's adjusted earnings per share for 2009 and be slightly accretive in 2010.
Sym-Bio Lifescience is a supplier of diagnostics to hospitals in China, particularly in the area of infectious diseases.
The acquisition doubles Perkin Elmer's access to the hospitals market segment in China, offering a larger base from which to expand its prenatal and newborn screening business in the country, and provides the company with a local diagnostics manufacturing and R+D base.
The addition of Sym-Bio's infectious disease products complements Perkin Elmer's position in prenatal and neonatal screening, providing a line of diagnostics for expansion of the company's regional and global offerings.
As part of the acquisition, Perkin Elmer gains access to manufacturing plant capacity in Shanghai and the surrounding area, where the company will be able to expand local production capabilities for a number of Perkin Elmer products in China, in addition to the diagnostics portfolio.
